Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

136 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Propensity Score-matched Comparison of Infliximab and Adalimumab in Tumour Necrosis Factor-α Inhibitor-naïve and Non-naïve Patients With Crohn's Disease: Real-Life Data From the Sicilian Network for Inflammatory Bowel Disease.
Macaluso FS, Fries W, Privitera AC, Cappello M, Siringo S, Inserra G, Magnano A, Di Mitri R, Mocciaro F, Belluardo N, Scarpulla G, Magrì G, Trovatello A, Carroccio A, Genova S, Bertolami C, Vassallo R, Romano C, Citrano M, Accomando S, Ventimiglia M, Renna S, Orlando R, Rizzuto G, Porcari S, Ferracane C, Cottone M, Orlando A; Sicilian Network for Inflammatory Bowel Diseases [SN-IBD]. Macaluso FS, et al. Among authors: belluardo n. J Crohns Colitis. 2019 Feb 1;13(2):209-217. doi: 10.1093/ecco-jcc/jjy156. J Crohns Colitis. 2019. PMID: 30295785
The real-world effectiveness of vedolizumab on intestinal and articular outcomes in inflammatory bowel diseases.
Macaluso FS, Orlando R, Fries W, Scolaro M, Magnano A, Pluchino D, Cappello M, Morreale GC, Siringo S, Privitera AC, Ferracane C, Belluardo N, Alberghina N, Ventimiglia M, Rizzuto G, Renna S, Cottone M, Orlando A. Macaluso FS, et al. Among authors: belluardo n. Dig Liver Dis. 2018 Jul;50(7):675-681. doi: 10.1016/j.dld.2018.02.013. Epub 2018 Mar 1. Dig Liver Dis. 2018. PMID: 29576495
Persistence on Anti-Tumour Necrosis Factor Therapy in Older Patients with Inflammatory Bowel Disease Compared with Younger Patients: Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD).
Porcari S, Viola A, Orlando A, Privitera AC, Ferracane C, Cappello M, Vitello A, Siringo S, Inserra G, Magnano A, Mocciaro F, Di Mitri R, Belluardo N, Fidanza O, Garufi S, Magrì G, Bertolami C, Carroccio A, Macaluso FS, Renna S, Ventimiglia M, Alibrandi A, Cottone M, Fries W; Sicilian Network for Inflammatory Bowel Diseases (SN-IBD). Porcari S, et al. Among authors: belluardo n. Drugs Aging. 2020 May;37(5):383-392. doi: 10.1007/s40266-020-00744-3. Drugs Aging. 2020. PMID: 32016824
The SPOSIB SB2 Sicilian Cohort: Safety and Effectiveness of Infliximab Biosimilar SB2 in Inflammatory Bowel Diseases, Including Multiple Switches.
Macaluso FS, Fries W, Viola A, Centritto A, Cappello M, Giuffrida E, Privitera AC, Piccillo G, Magnano A, Vinci E, Vassallo R, Trovatello A, Belluardo N, Giangreco E, Camilleri S, Garufi S, Bertolami C, Ventimiglia M, Renna S, Orlando R, Rizzuto G, Orlando A. Macaluso FS, et al. Among authors: belluardo n. Inflamm Bowel Dis. 2021 Jan 19;27(2):182-189. doi: 10.1093/ibd/izaa036. Inflamm Bowel Dis. 2021. PMID: 32083291
A propensity score weighted comparison of vedolizumab and adalimumab in Crohn's disease.
Macaluso FS, Ventimiglia M, Fries W, Viola A, Sitibondo A, Cappello M, Scrivo B, Busacca A, Privitera AC, Camilleri S, Garufi S, Di Mitri R, Mocciaro F, Belluardo N, Giangreco E, Bertolami C, Renna S, Orlando R, Rizzuto G, Cottone M, Orlando A; Sicilian Network for Inflammatory Bowel Disease (SN-IBD). Macaluso FS, et al. Among authors: belluardo n. J Gastroenterol Hepatol. 2021 Jan;36(1):105-111. doi: 10.1111/jgh.15107. Epub 2020 Jun 8. J Gastroenterol Hepatol. 2021. PMID: 32428981
Effectiveness and safety of vedolizumab in biologically naïve patients: A real-world multi-centre study.
Macaluso FS, Fries W, Renna S, Viola A, Muscianisi M, Cappello M, Guida L, Siringo S, Camilleri S, Garufi S, Privitera AC, Belluardo N, Giangreco E, Bertolami C, Vassallo R, Rizzuto G, Orlando R, Ventimiglia M, Orlando A; Sicilian Network for Inflammatory Bowel Disease (SN-IBD). Macaluso FS, et al. Among authors: belluardo n. United European Gastroenterol J. 2020 Nov;8(9):1045-1055. doi: 10.1177/2050640620948802. Epub 2020 Aug 9. United European Gastroenterol J. 2020. PMID: 32772830 Free PMC article.
SPOSAB ABP 501: A Sicilian Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Adalimumab Biosimilar ABP 501.
Macaluso FS, Cappello M, Busacca A, Fries W, Viola A, Costantino G, Magnano A, Vinci E, Ferracane C, Privitera AC, Piccillo G, Belluardo N, Giangreco E, Romano C, Citrano M, Graziano F, Garufi S, Bertolami C, Ventimiglia M, Scrivo B, Teresi G, Renna S, Rizzuto G, Casà A, Orlando A; Sicilian Network for Inflammatory Bowel Disease (SN-IBD). Macaluso FS, et al. Among authors: belluardo n. J Gastroenterol Hepatol. 2021 Nov;36(11):3041-3049. doi: 10.1111/jgh.15590. Epub 2021 Jul 3. J Gastroenterol Hepatol. 2021. PMID: 34152636
Vedolizumab may be an effective option for the treatment of postoperative recurrence of Crohn's disease.
Macaluso FS, Cappello M, Crispino F, Grova M, Privitera AC, Piccillo G, Magnano A, Ferracane C, Belluardo N, Giangreco E, Fries W, Viola A, Di Mitri R, Mocciaro F, Camilleri S, Garufi S, Renna S, Casà A, Maida M, Orlando A; Sicilian Network for Inflammatory Bowel Disease (SN-IBD). Macaluso FS, et al. Among authors: belluardo n. Dig Liver Dis. 2022 May;54(5):629-634. doi: 10.1016/j.dld.2021.11.021. Epub 2021 Dec 16. Dig Liver Dis. 2022. PMID: 34924320
Ustekinumab is a promising option for the treatment of postoperative recurrence of Crohn's disease.
Macaluso FS, Grova M, Mocciaro F, Di Mitri R, Privitera AC, Distefano ME, Vitello A, Camilleri S, Ferracane C, Pluchino D, Belluardo N, Giangreco E, Fries W, Viola A, Cappello M, D'Amato L, Bertolami C, Ventimiglia M, Renna S, Casà A, D'Antonio E, De Vivo S, Orlando A; Sicilian Network for Inflammatory Bowel Disease (SN-IBD). Macaluso FS, et al. Among authors: belluardo n. J Gastroenterol Hepatol. 2023 Sep;38(9):1503-1509. doi: 10.1111/jgh.16208. Epub 2023 May 6. J Gastroenterol Hepatol. 2023. PMID: 37148148
136 results